HomeAI · summaries
Storia in 7 fonti
Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients
In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept at playing catch-up with Novo Nordisk. | In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept at playing catch-up with Novo Nordisk. On Friday, Lilly checked another item off that list as it secured FDA approval for Mounjaro to reduce the risk of heart attack or stroke in at-risk adults with type 2 diabetes.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercehealthcare.com
Eli Lilly study aims to bolster case for long-term Zepbound benefits
As Medicare's GLP-1 Bridge program gets underway in earnest and questions remain about the long-term use of these drugs, Eli Lilly is offering a new look at how older adults fare…
- ·
morningstar.com
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
